Physician profile
Sarah E Hale
NPI 1053843219
$11,038.10
in general payments reported to CMS, 2019-2025
9 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.91 · 2023: $11K · 2024: $145 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $11K · Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,500.00 |
| Food and Beverage | $510.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $10,694.10 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $90.76 | 2023 | Amvuttra |
| Pfizer INC. | $54.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.85 | 2024-2025 | Camzyos |
| Abiomed | $41.26 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $32.29 | 2025 | Wainua |
| Angiodynamics, INC. | $27.91 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.79 | 2024 | Lifevest |
| Scpharmaceuticals INC. | $21.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.